Literature DB >> 17412461

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.

Iain Stephenson1, Rose Gaines Das, John M Wood, Jacqueline M Katz.   

Abstract

A study was performed to investigate the reproducibility of haemagglutinin-inhibition (HI) and virus neutralising (VN) assays for detection of anti-influenza antibody. Participants in 11 laboratories from eight countries measured antibody to egg-grown A/Japan/434/2003, cell-grown A/Japan/434/2003 and A/Panama/2007/99 (H3N2) viruses in 18 human and two post-infection ferret sera. There was significant intra-laboratory assay variability for VN compared to HI. For replicate assays within laboratories, 14/410 (3%) and 130/631 (21%) titres differed by >2-fold (p<0.0001), and 0/410 (0%) and 35/631 (6%) titres differed by >5-fold (p<0.0001) by HI and VN, respectively. Although both assays showed inter-laboratory variation, VN assays were significantly more variable than HI. Median geometric coefficients of variation (GCV) for VN assays with each virus were 256%, 323% and 359% compared to 138%, 155% and 261% with HI. A serum standard improved inter-laboratory agreement and reduced median GCVs. This study raises concern about comparability of serology results from H5N1 vaccine trials and it is proposed that an International Standard for influenza H5N1 antibody is developed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412461     DOI: 10.1016/j.vaccine.2007.02.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

1.  Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.

Authors:  Mary Zacour; Brian J Ward; Angela Brewer; Patrick Tang; Guy Boivin; Yan Li; Michelle Warhuus; Shelly A McNeil; Jason J LeBlanc; Todd F Hatchette
Journal:  Clin Vaccine Immunol       Date:  2016-01-27

2.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

3.  Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.

Authors:  Shahzma Merani; George A Kuchel; Alison Kleppinger; Janet E McElhaney
Journal:  Exp Gerontol       Date:  2017-09-27       Impact factor: 4.032

Review 4.  Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

Authors:  Thomas Hagan; Helder I Nakaya; Shankar Subramaniam; Bali Pulendran
Journal:  Vaccine       Date:  2015-04-06       Impact factor: 3.641

5.  Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season.

Authors:  Jill J Severson; Katelyn R Richards; John J M Moran; Mary S Hayney
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

6.  Herd immunity to GII.4 noroviruses is supported by outbreak patient sera.

Authors:  Jennifer L Cannon; Lisa C Lindesmith; Eric F Donaldson; Lauryn Saxe; Ralph S Baric; Jan Vinjé
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

7.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

8.  Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Authors:  Dominick J Laddy; Jian Yan; Amir S Khan; Hanne Andersen; Amanda Cohn; Jack Greenhouse; Mark Lewis; Jody Manischewitz; Lisa R King; Hana Golding; Ruxandra Draghia-Akli; David B Weiner
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Reproducibility of serologic assays for influenza virus A (H5N1).

Authors:  Iain Stephenson; Alan Heath; Diane Major; Robert W Newman; Katja Hoschler; Wang Junzi; Jacqueline M Katz; Jerry P Weir; Maria C Zambon; John M Wood
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

10.  A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice.

Authors:  Arnt-Ove Hovden; Karl A Brokstad; Diane Major; John Wood; Lars R Haaheim; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2009-01       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.